Edoardo Garbo
A5009609652- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Multiple and Secondary Primary Cancers
- Peptidase Inhibition and Analysis
- RNA modifications and cancer
- Cancer therapeutics and mechanisms
- SARS-CoV-2 and COVID-19 Research
- Angiogenesis and VEGF in Cancer
- Breast Cancer Treatment Studies
- Vaccine Coverage and Hesitancy
- Chronic Lymphocytic Leukemia Research
- Cancer-related molecular mechanisms research
- Melanoma and MAPK Pathways
- Cancer Cells and Metastasis
- PI3K/AKT/mTOR signaling in cancer
- Esophageal Cancer Research and Treatment
- Cancer survivorship and care
- Cytokine Signaling Pathways and Interactions
- MicroRNA in disease regulation
- Cancer Mechanisms and Therapy
University of Turin
2022-2025
Dana-Farber Cancer Institute
2024-2025
Ospedale San Luigi Gonzaga
2022-2025
Harvard University
2024
Mutations in the RAS–RAF–MEK–ERK pathway are frequent alterations cancer and RASopathies, while RAS oncogene activation alone affects 19% of all patients accounts for approximately 3.4 million new cases every year, less cascade's downstream effectors also involved etiology. proteins initiate signaling cascade by promoting dimerization RAF kinases, which can act as oncoproteins well: BRAF V600E is most common oncogenic driver, mutated 8% malignancies. Research this field led to development...
Background Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its long-term efficacy remains sparse. Methods This study assessed 5-year outcomes of first-line pembrolizumab in a large, multicenter, cohort patients NSCLC and PD-L1 TPS≥50%, referred to as Pembro-real 5Y. Individual patient-level (IPD) from the experimental arm...
Sotorasib showed a significant improvement of progression free survival (PFS), safety and quality life over docetaxel in patients with KRASp.G12C-mutated advanced non-small-cell lung cancer (NSCLC) within the CodeBreak-200 study. Here we report real-world efficacy tolerability data from NSCLC who received sotorasib Italian expanded access program (EAP).
To date, precision medicine has revolutionized the clinical management of Non-Small Cell Lung Cancer (NSCLC). International societies approved a rapidly improved mandatory testing biomarkers panel for stratification NSCLC patients, but harmonized procedures are required to optimize diagnostic workflow. In this context knowledge-based database (Biomarkers ATLAS, https://biomarkersatlas.com/) was developed by supervising group expert pathologists and thoracic oncologists collecting updated...
<h3>Background</h3> Pembrolizumab monotherapy is established as an effective front-line treatment for advanced non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50%. However, real-world data on its long-term efficacy remains sparse. <h3>Methods</h3> This study assessed 5-year outcomes of first-line pembrolizumab in a large, multicenter, cohort patients NSCLC and TPS Individual patient-level (IPD) from the experimental arm Keynote-024 trial were extracted (KN024 IPD...
Safety data regarding BNT162b2 in cancer patients (CPs) are scarce. Herein we report the side effects (SEs), adverse events (AEs), and patient-reported outcomes (PROs) following administration CPs treated at San Luigi Gonzaga University Hospital. All who agreed to participate our vaccination campaign received were included descriptive analysis. An anonymous questionnaire investigating occurrence of SEs/AEs PROs was administered study population 21 days after first dose. Pearson's chi-squared...